Featured Tickers:
Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Ocular Therapeutix, Inc., Tilray Brands or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Ocular Therapeutix, Inc., Tilray Brands and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Ocular Therapeutix, Inc., Tilray Brands and Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte’s Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Cruisies, Atwater Brewery, Hiball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner’s High Brewing Company, SweetWater Brewing Company, Terrapin Beer Co., Happy Flower, Fizzy Jane’s, Herb & Bloom, 420 Fizz, and Fresh Hemp Foods brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Latest Pharmaceuticals and Ocular Therapeutix, Inc., Tilray Brands, Inc. Stock News
As of September 29, 2025, Ocular Therapeutix, Inc. had a $2.2 billion market capitalization, compared to the Pharmaceuticals median of $344.0 million. Ocular Therapeutix, Inc.’s stock is up 46.7% in 2025, up 2% in the previous five trading days and up 41.74% in the past year.
Currently, Ocular Therapeutix, Inc. does not have a price-earnings ratio. Ocular Therapeutix, Inc.’s trailing 12-month revenue is $56.7 million with a -382.5% net profit margin. Year-over-year quarterly sales growth most recently was -17.7%. Analysts expect adjusted earnings to reach $-1.493 per share for the current fiscal year. Ocular Therapeutix, Inc. does not currently pay a dividend.
As of September 29, 2025, Tilray Brands, Inc. had a $2.1 billion market cap, putting it in the 57th percentile of all stocks. Tilray Brands, Inc.’s stock is up 39.1% in 2025, up 50.4% in the previous five trading days and up 10.12% in the past year.
Currently, Tilray Brands, Inc. does not have a price-earnings ratio. Tilray Brands, Inc.’s trailing 12-month revenue is $821.3 million with a -266.3% net profit margin. Year-over-year quarterly sales growth most recently was -2.3%. There are no analysts providing consensus earnings estimates for the current fiscal year. Tilray Brands, Inc. does not currently pay a dividend.
How We Compare Ocular Therapeutix, Inc., Tilray Brands and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Ocular Therapeutix, Inc., Tilray Brands and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions